Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment

Vensica Medical (“Vensica”), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round. The investment will fund the company’s upcoming Phase 2 clinical trials across the United States and Europe for its revolutionary treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin^®) delivered through a proprietary, needle-free device.

The investment round was led by Israel Biotech Fund (IBF), alongside key strategic partners, Merz, a global player in neurotoxins, and Laborie, a prominent urology medical device company. This funding will enable Vensica to continue its mission of providing a minimally invasive, simple, and effective solution for people with overactive bladder (“OAB”).

Vensica’s unique technology leverages a needle-free drug delivery system, that administers Xeomin^® directly to the bladder wall. This approach is expected to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica’s needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications.

As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin^® in needle-less therapeutic application in several urologic indications and will benefit from Merz’s clinical development support. This collaboration marks a significant step forward in the company’s goal of delivering next-generation urology treatments.

This news appeared in: Pharma Era, Calcalist, and PRNewswire